p53 and PCNA expression in benign, atypical and malignant meningiomas.
OBJECTIVE
Alterations: p53 genes are turning out to be the most common genetic alterations in human cancers. Due to long half-life of mutated p53, its detection is possible by immunohistochemistry. Proliferating cell nuclear antigen (PCNA) is expressed by dividing cells, hence has been shown to correlate with prognosis. We have used monoclonal antibodies protein DO-7 (p53) and PC10 (PCNA) to see whether their expression correlates with histological grading in meningethelial tumour.


METHODS
Twenty nine meningiomas (20 benign, 7 atypical and 2 malignant) were selected from the records of our laboratory. p53 and PCNA expression was sought by immunohistochemistry using Peroxidase Anti Peroxidase (PAP) technique.


RESULTS
Four benign and 2 atypical meningiomas showed weak staining for p53. Both malignant meningiomas showed strong positivity for p53. Six benign meningiomas had less than 5% PCNA positivity, one 10% positivity and three showed 20% positivity. PCNA positivity ranged for 10-80% in atypical meningiomas. In two malignant meningiomas PCNA positivity was 70% and 90%.


CONCLUSIONS
It is worthwhile to include p53 and PCNA expression along with histologic assessment in predicting outcome of meningiomas. A larger series with complete follow-up is essential in assessing value of these markers which unfortunately remains a dream in our country.
Ahmed
R
R
Department of Pathology, Aga Khan University Hospital, Karachi.
Soomro
I N
IN
Aziz
S A
SA
Hasan
S H
SH
D006801:Humans; D008577:Meningeal Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D008579:Meningioma / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D009361:Neoplasm Invasiveness; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000097:blood*; D011446:Prospective Studies; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53